MX2021006702A - Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen. - Google Patents

Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen.

Info

Publication number
MX2021006702A
MX2021006702A MX2021006702A MX2021006702A MX2021006702A MX 2021006702 A MX2021006702 A MX 2021006702A MX 2021006702 A MX2021006702 A MX 2021006702A MX 2021006702 A MX2021006702 A MX 2021006702A MX 2021006702 A MX2021006702 A MX 2021006702A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
compositions containing
crystalline forms
mcl
inhibitor
Prior art date
Application number
MX2021006702A
Other languages
English (en)
Spanish (es)
Inventor
Michael Lynch
Baets Emilie De
Julien Auvray
Nicolas Leblanc
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2021006702A publication Critical patent/MX2021006702A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021006702A 2018-12-06 2019-12-05 Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen. MX2021006702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306634 2018-12-06
PCT/EP2019/083773 WO2020115183A1 (en) 2018-12-06 2019-12-05 New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.

Publications (1)

Publication Number Publication Date
MX2021006702A true MX2021006702A (es) 2021-07-07

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006702A MX2021006702A (es) 2018-12-06 2019-12-05 Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen.

Country Status (26)

Country Link
US (2) US12129261B2 (https=)
EP (1) EP3891156B1 (https=)
JP (1) JP7649241B2 (https=)
KR (1) KR102855345B1 (https=)
CN (1) CN113166169A (https=)
AR (1) AR117255A1 (https=)
AU (1) AU2019391329B2 (https=)
BR (1) BR112021010072A2 (https=)
CA (1) CA3121363A1 (https=)
DK (1) DK3891156T3 (https=)
EA (1) EA202191534A1 (https=)
ES (1) ES2971258T3 (https=)
FI (1) FI3891156T3 (https=)
HR (1) HRP20240211T1 (https=)
HU (1) HUE065266T2 (https=)
IL (1) IL283656B2 (https=)
LT (1) LT3891156T (https=)
MA (1) MA54379B1 (https=)
MD (1) MD3891156T2 (https=)
MX (1) MX2021006702A (https=)
PL (1) PL3891156T3 (https=)
PT (1) PT3891156T (https=)
RS (1) RS65047B1 (https=)
SI (1) SI3891156T1 (https=)
TW (1) TWI905090B (https=)
WO (1) WO2020115183A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2020115183A1 (en) 2020-06-11
SI3891156T1 (sl) 2024-03-29
KR20210100148A (ko) 2021-08-13
EA202191534A1 (ru) 2021-10-27
KR102855345B1 (ko) 2025-09-03
FI3891156T3 (fi) 2024-02-07
PL3891156T3 (pl) 2024-05-13
TWI905090B (zh) 2025-11-21
HRP20240211T1 (hr) 2024-04-26
MA54379A (fr) 2021-10-13
BR112021010072A2 (pt) 2021-08-24
CN113166169A (zh) 2021-07-23
JP7649241B2 (ja) 2025-03-19
US20220017533A1 (en) 2022-01-20
EP3891156B1 (en) 2023-11-15
MD3891156T2 (ro) 2024-06-30
AU2019391329A1 (en) 2021-07-01
LT3891156T (lt) 2023-12-27
DK3891156T3 (da) 2024-02-19
EP3891156A1 (en) 2021-10-13
IL283656B1 (en) 2025-06-01
TW202039511A (zh) 2020-11-01
IL283656B2 (en) 2025-10-01
ES2971258T3 (es) 2024-06-04
IL283656A (en) 2021-07-29
CA3121363A1 (en) 2020-06-11
JP2022511495A (ja) 2022-01-31
MA54379B1 (fr) 2023-12-29
HUE065266T2 (hu) 2024-05-28
NZ776907A (en) 2025-05-02
AU2019391329B2 (en) 2024-09-26
US20250011337A1 (en) 2025-01-09
RS65047B1 (sr) 2024-02-29
US12129261B2 (en) 2024-10-29
AR117255A1 (es) 2021-07-21
PT3891156T (pt) 2024-01-16

Similar Documents

Publication Publication Date Title
CL2019003154A1 (es) Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)
MX2019015744A (es) Composiciones farmaceuticas.
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
TN2018000239A1 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
MX390287B (es) Composiciones farmacéuticas que contienen derivados de piridona policíclicos sustituidos y profármacos de los mismos.
CL2022000201A1 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
AR104505A1 (es) Formas sólidas
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CO2019013823A2 (es) Compuestos heteroaromáticos como inhibidores de vanina
BR112018007381A2 (pt) compostos úteis como imunomoduladores
UY37289A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
MX2019014054A (es) Profarmacos de glucuronida de inhibidores de la cinasa janus.
UY35356A (es) Nueva sal de abexinostat, forma cristalina asociada, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
UY39153A (es) Metilación de compuestos mcl-1
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CL2021000947A1 (es) Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contienen la misma.
MX2021006702A (es) Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen.
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
CL2020000217A1 (es) Inhibidores de ror gamma.
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
MX2022001608A (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso.
CL2021000973A1 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.